Clearing the Arterial Graveyard: Rapamycin Recharges Cellular Clean-Up Crews to Shrink Atherosclerotic Plaques

News
#1

RapArteries2
RapArteries22752×1536 462 KB

Atherosclerotic plaques expand dangerously when scavenger immune cells called macrophages fail to clear dying cells, a failure compounded by iron-driven oxidative cell damage known as ferroptosis. Examining both human endarterectomy tissues and mouse vascular models, researchers discovered that advanced plaques suffer from a severe breakdown in GPX4-mediated antioxidant defense, mitochondrial collapse, and loss of the clearance receptors MERTK and MFG-E8. Administering low-dose systemic rapamycin preserved mitochondrial energetics, suppressed iron-mediated lipid peroxidation, revived macrophage clearance capability, and cut whole-aorta plaque lipid burden by more than half while substantially increasing plaque-stabilizing collagen.

The defining crisis of advanced arterial disease is necrotic debris accumulation. As blood vessels accrue cholesterol, local macrophages ingest lipids until they become foam cells. In early stages, dying cells undergo efferocytosis, an orderly biological engulfment and waste-processing cycle that prevents intracellular contents from spilling into surrounding tissue. In mature lesions, this process falters. Uncleared apoptotic corpses undergo secondary necrosis, expelling inflammatory compounds, enzymatic debris, and crystalline lipids into the vessel wall. This cycle creates a growing, unstable necrotic core prone to catastrophic rupture.

A primary driver of this efferocytic collapse is ferroptosis, an iron-catalyzed cascade of lipid peroxidation that damages delicate subcellular membranes. Analyzing human carotid plaque samples harvested during vascular surgery, researchers observed that the primary lipid-peroxide neutralizer, glutathione peroxidase 4 (GPX4), was severely depleted in advanced fibrous lesions relative to adjacent early lesions. This deficiency leaves vascular macrophages defenseless against oxidative stress. Without functional GPX4, intracellular iron accelerates the peroxidation of polyunsaturated fatty acids, triggering mitochondrial calcium overload, membrane potential breakdown, and acute energy exhaustion. Because the mechanical engulfment of dying cells requires substantial cellular energy, energy-depleted macrophages shed their primary phagocytic tethering molecules, MERTK and MFG-E8.

The investigative team modeled this pathway in human macrophages using the chemical compound FIN-56, reproducing the cellular damage, glycolytic shift, and clearance deficits seen in diseased vessels. Co-treatment with rapamycin rescued these cellular cohorts. By dampening baseline mTOR activity, rapamycin restored GPX4 expression, lowered intracellular free iron and toxic lipid aldehydes, and preserved oxygen consumption and cellular energy production. Macrophages regained their physical capacity to bind and internalize dying cells. Crucially, the compound also stopped surrounding vascular smooth muscle cells from adopting a harmful synthetic phenotype that accelerates arterial disease.

In an animal model using genetically susceptible mice fed an atherogenic high-fat diet, a four-week regimen of twice-weekly rapamycin reversed established vascular decay. The treatment restored the ratio of active clearance events relative to free-floating dying cells from 0.37 to 1.37, while dropping lipid deposition across the entire length of the aorta from 25.32 percent down to 12.28 percent. Plaque coverage at the aortic root dropped from 35.56 percent to 16.71 percent, while protective fibrous collagen caps expanded from 22.42 percent to 39.73 percent. These findings indicate that rapamycin works in part by rescuing macrophage vitality and restoring cellular housekeeping.

Actionable Insights

This paper highlights that arterial plaque stability depends heavily on the energy status of tissue-resident macrophages and their capacity to clear cellular waste. The practical takeaway centers on the potential of targeted mTOR modulation and lipid antioxidant support to resolve vascular inflammation.

In mice, low-dose rapamycin produced an absolute reduction of 13.04 percentage points in aortic lipid accumulation (falling from 25.32% to 12.28%, a relative reduction of 51.5%), while reducing the aortic root plaque footprint by an absolute 18.85 percentage points (falling from 35.56% to 16.71%, a relative reduction of 53.0%). Concurrently, it produced an absolute increase of 17.31 percentage points in structural collagen (rising from 22.42% to 39.73%, a relative improvement of 77.2%), and improved the cellular clearance index nearly fourfold (increasing from 0.37 to 1.37).

These findings suggest that strategies preserving mitochondrial glutathione pools, minimizing systemic iron overload, and periodically attenuating hyperactive mTOR signaling may help stabilize existing plaques. The data also support the clinical development of drug-coated balloons that deliver rapamycin locally to damaged blood vessels, securing these cellular benefits without causing systemic harm.

Context and Source

  • Paywalled Paper: Rapamycin attenuates ferroptotic stress and improves macrophage efferocytosis in experimental atherosclerosis, 2026 Oct 2.
  • Primary Institutions: Department of Cerebrovascular Diseases, People’s Hospital of Zhengzhou University (Henan Provincial People’s Hospital); Henan International Joint Laboratory of Cerebrovascular Diseases, Zhengzhou, China
  • Journal Name: International Immunopharmacology
  • Impact Evaluation: The impact score of this journal is 5.6 (Clarivate Web of Science Journal Impact Factor), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

Related Reading:

#2

Biomarker Data (Effect Size Extraction)

The physiological and histological endpoints demonstrated substantial effect magnitudes:

  • In Vivo Efferocytosis Index: The ratio of macrophage-associated apoptotic cells to free apoptotic cells inside plaques was 0.37 +/- 0.15 in HD mice versus 1.37 +/- 0.15 in HD + Rapa mice (standard normal chow controls exhibited 2.19 +/- 0.08). This represents an absolute increase of 1.00 unit and a relative gain of 270.3%. The standardized effect size (Cohen’s d) between HD and HD + Rapa exceeds 6.6, indicating a very large rescue effect. [Confidence: High]
  • Whole-Aorta En Face Lipid Area: Dropped from 25.32% +/- 0.98% in the HD group to 12.28% +/- 1.49% in the HD + Rapa group (versus 1.35% +/- 0.52% in ND controls). This represents an absolute reduction of 13.04 percentage points and a relative reduction of 51.5% (Cohen’s d = 10.3). [Confidence: High]
  • Aortic Root Plaque Area (Percent of Luminal Area): Dropped from 35.56% +/- 3.73% to 16.71% +/- 0.81% following rapamycin (versus 6.72% +/- 0.44% in ND controls), reflecting an absolute reduction of 18.85 percentage points and a relative reduction of 53.0% (Cohen’s d = 6.9). [Confidence: High]
  • Plaque Fibrous Collagen Area: Increased from 22.42% +/- 3.99% in HD mice to 39.73% +/- 2.21% in HD + Rapa mice (ND baseline: 47.78% +/- 0.57%), reflecting an absolute gain of 17.31 percentage points and a relative improvement of 77.2% (Cohen’s d = 5.3). [Confidence: High]
  • Tissue Malondialdehyde (MDA/TBARS): Decreased from a 1.76 +/- 0.12 fold increase over baseline in HD mice down to 1.38 +/- 0.08 fold in the HD + Rapa cohort, reflecting an absolute reduction of 0.38 fold units and an attenuation of 21.6% (Cohen’s d = 3.7). [Confidence: High]
  • Tissue Non-Heme Iron Burden: Lowered from 1.96 +/- 0.17 fold over baseline in the HD group to 1.25 +/- 0.08 fold in the rapamycin group, an absolute decrease of 0.71 fold units and a relative reduction of 36.2% (Cohen’s d = 5.3). [Confidence: High]
  • In Vitro Phagocytic Capacity: Flow-cytometric clearance of apoptotic cells by viable macrophages dropped from 27.23% +/- 2.01% in untreated controls to 15.63% +/- 1.44% under FIN-56 stress, and was rescued to 28.53% +/- 1.40% by rapamycin co-treatment, representing an absolute recovery of 12.90 percentage points and a relative restoration of 82.5% (Cohen’s d = 9.1). [Confidence: High]

Novelty

Prior research established that ferroptosis promotes vascular injury and that rapamycin stabilizes plaques through general antiproliferative, anti-inflammatory, and autophagy-inducing mechanisms. The primary advance of this paper is demonstrating that ferroptotic stress impairs efferocytosis by inducing mitochondrial respiratory collapse and downregulating the clearance receptors MERTK and MFG-E8. Furthermore, it shows that these functional defects can be reversed by pharmacologically inhibiting mTOR or targeting mitochondrial ROS with MitoTEMPO, linking ferroptosis defense directly to the mechanical clearance of dead cells.

#3

There seem to be some differences in the outcomes in this study compared to this other paper: Rapamycin Quiets the Aging Immune System Around Arterial Plaques

So I’ve asked Google Gemini to Compare, contrast, and summarize any key claims differences between these two papers. Following is the response:

Paper comparison:

The two papers analyze systemic rapamycin administration in murine atherosclerosis models but diverge fundamentally in their experimental designs, proposed mechanisms of action, and macroscopic vascular outcomes[cite: 1, 22]. Wang et al. frames rapamycin as a rescue agent for localized innate macrophage metabolism that physically shrinks plaques in young subjects[cite: 1, 12]. Smit et al. positions rapamycin as a systemic immune rejuvenation therapy that remodels adaptive lymphocyte populations but fails to reduce physical plaque size in advanced age[cite: 22, 27].

Experimental Design Comparison

Parameter Wang et al. (Paper 1) Smit et al. (Paper 2)
Animal Model Young ApoE-/- mice[cite: 2] Aged Ldlr-/- mice (80 to 90 weeks old)[cite: 24]
Dietary Trigger 12 weeks of High-Fat Diet[cite: 2] Lifelong standard chow diet[cite: 24]
Rapamycin Dosing 1 mg/kg intravenously, twice weekly for 4 weeks[cite: 3] 1 mg/kg intraperitoneally, three times weekly for 8 weeks[cite: 24, 27]
Primary Immune Focus Innate immunity (Macrophage efferocytosis)[cite: 1, 6] Adaptive immunity (T cells and B cells)[cite: 22, 28]

Key Claims Differences

  • Plaque Morphology and Regression: Wang et al. assert that rapamycin actively reduces whole-aorta lipid deposition and aortic root plaque area while increasing structural collagen[cite: 1, 12, 17]. Smit et al. counter this by demonstrating that in an aged model with established disease, 8 weeks of higher-frequency rapamycin dosing fails to alter overall plaque size, volume, necrotic core area, or collagen content[cite: 27].
  • Systemic Lipid Dynamics: Smit et al. observe that rapamycin significantly elevates systemic serum cholesterol levels[cite: 27, 35]. Wang et al. focus exclusively on the drug’s ability to lower local lipid peroxidation and iron accumulation within the vascular tissue itself, omitting systemic cholesterol variations[cite: 6, 8, 12].
  • Immunological Paradigms: Wang et al. claim that atherosclerosis progression is dictated by localized cellular exhaustion, specifically macrophage ferroptosis and the resulting inability to clear dead cells from the arterial wall[cite: 1, 8, 15]. Smit et al. claim the driving pathology in late-stage disease is systemic immunosenescence[cite: 22, 23]. They demonstrate that rapamycin sharply reduces total immune cell counts in regional lymph nodes, diminishes age-associated B cells, and shifts the T cell compartment away from an active effector state toward a regulatory T cell dominant state[cite: 22, 28, 30].
  • Macrophage Reduction Drivers: Both papers confirm a reduction in plaque macrophage content[cite: 17, 27]. Wang et al. credit this to localized metabolic rescue and prevented cell death[cite: 1, 12]. Smit et al. suggest the reduction is secondary to the profound suppression of systemic lymphocyte signaling, which dampens overall monocyte recruitment to the plaque[cite: 28, 34].

Knowledge Gaps and Scholarly Debates

The direct conflict in macroscopic plaque outcomes highlights a critical knowledge gap regarding the timing of mTOR inhibition in cardiovascular disease. It remains uncertain whether rapamycin physically regresses early, lipid-driven plaques as seen in Wang et al. but loses this structural efficacy in the highly senescent, calcified lesions typical of the 80-week-old cohort used by Smit et al.[cite: 12, 27, 34]. Additional longitudinal data is required to determine if the systemic cholesterol elevation induced by chronic rapamycin therapy necessitates concurrent statin administration to achieve physical plaque regression in elderly subjects[cite: 35].

Actionable Longevity Insights

For clinical longevity and healthspan optimization, these papers collectively establish that mTOR inhibition acts as a potent immune modulator but carries context-dependent vascular risks[cite: 1, 22]. Rapamycin therapy effectively dampens age-related systemic inflammation, preserves regulatory T cell populations, and prevents localized cellular oxidative collapse[cite: 12, 22, 34]. However, individuals utilizing rapamycin for systemic rejuvenation must actively monitor lipid panels. The therapy can elevate systemic cholesterol, which may neutralize its localized arterial benefits and stall plaque regression if the hyperlipidemia is left unmanaged[cite: 27, 35].

References

#4

Follow-on Prompt:

Considering the best established cardiology and atherosclerosis expertise, and understanding of the different mouse models used and their predispositions, age of animals, and treatment durations and diet, What are the most likely reasons for the differences in the two studies regarding outcomes in the plaque morphology and regression?

Google Gemini Pro (extended) Response:

The conflicting outcomes in macroscopic plaque regression between these two studies represent artifacts of experimental design rather than contradictory pharmacology [Confidence: High]. The structural differences in plaque morphology response stem directly from the interplay between plaque maturity, the specific genetic knockouts utilized, and the dietary kinetics driving the disease models.

  • Plaque Maturity and Structural Plasticity: The Wang study utilized mice euthanized at approximately 24 weeks of age. Plaques at this stage, particularly after acute high fat diet feeding, are highly cellular, lipid-rich, and driven by active macrophage infiltration. These soft lesions retain structural plasticity and can rapidly shrink when macrophage efferocytosis is restored and localized oxidative stress is halted. Conversely, the Smit study utilized geriatric mice aged 80 to 90 weeks. Decades of equivalent human aging translate to advanced, fibrotic, necrotic, and heavily cross-linked hard plaques. Suppressing immune signaling in late-stage disease does not physically dissolve established extracellular matrix or dense cholesterol crystals. [Confidence: High]

  • Genotype-Specific Lipid Dynamics: The interaction between mTOR inhibition and specific genetic models dictates the systemic lipid environment. Ldlr-deficient mice lack the primary low-density lipoprotein receptor and rely on alternative pathways to clear circulating cholesterol. Rapamycin exacerbates hyperlipidemia by altering hepatic lipid processing, which the Smit study explicitly observed as a significant increase in total serum cholesterol. This continuous systemic atherogenic pressure offsets the local anti-inflammatory benefits within the arterial wall, maintaining the physical plaque volume. In contrast, ApoE-deficient mice suffer from impaired clearance of chylomicrons and very-low-density lipoprotein remnants. The acute attenuation of localized lipid peroxidation and ferroptosis by rapamycin in the Wang model appears to have outpaced any systemic lipid elevations, allowing for measurable morphological regression. [Confidence: Medium]

  • Dietary Kinetics and Disease Velocity: The Wang study forced acute atherogenesis using a 12-week high fat diet containing 21 percent fat and 0.15 percent cholesterol. Intervening in a fast-progressing, highly inflammatory acute disease state yields rapid morphological shifts when the primary metabolic stressor is modulated. The Smit study fed mice a standard chow diet for their entire lifespan. Atherosclerosis in this geriatric model develops via a chronic, slow-smoldering accumulation of damage. An 8-week intervention is mechanistically unlikely to reverse 80 weeks of gradual architectural remodeling. [Confidence: High]

  • Anabolic Suppression in Senescent Tissue: Rapamycin is a potent inhibitor of cellular proliferation and anabolic matrix synthesis. In the young ApoE model, dampening inflammation allowed relatively healthy local tissue to clear debris and stabilize the plaque. In the elderly Ldlr model, the vascular smooth muscle cells and resident fibroblasts are highly senescent. Blocking mTOR in senescent tissue further suppresses the tissue repair and remodeling capabilities necessary to physically alter the plaque architecture. [Confidence: Medium]

Clinical cardiology consistently demonstrates that resolving vascular inflammation prevents acute plaque rupture but fails to reduce plaque volume without aggressive, concurrent lipid lowering. The Smit model accurately reflects this geriatric clinical reality, where immune modulation cools the plaque but hyperlipidemia maintains its physical volume.